PUBLIC COMPANY
saveRAPT Therapeutics Inc
updated 17d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- GSK prepares for patent cliff with $2.5B cost-cutting planThe pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.biopharma_dive · 20d ago
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 20d ago
- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…biospace · 25d ago
comments(0)
5-min edit window · permanent after that